Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.62
NEPT's Cash to Debt is ranked lower than
74% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. NEPT: 1.62 )
Ranked among companies with meaningful Cash to Debt only.
NEPT' s 10-Year Cash to Debt Range
Min: 0.02  Med: 0.78 Max: No Debt
Current: 1.62
Equity to Asset 0.55
NEPT's Equity to Asset is ranked lower than
64% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NEPT: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NEPT' s 10-Year Equity to Asset Range
Min: -0.42  Med: 0.54 Max: 0.83
Current: 0.55
-0.42
0.83
F-Score: 2
Z-Score: 0.07
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -267.97
NEPT's Operating margin (%) is ranked lower than
65% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. NEPT: -267.97 )
Ranked among companies with meaningful Operating margin (%) only.
NEPT' s 10-Year Operating margin (%) Range
Min: -262.75  Med: -29.96 Max: -9.17
Current: -267.97
-262.75
-9.17
Net-margin (%) -196.76
NEPT's Net-margin (%) is ranked lower than
62% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. NEPT: -196.76 )
Ranked among companies with meaningful Net-margin (%) only.
NEPT' s 10-Year Net-margin (%) Range
Min: -185.54  Med: -36.54 Max: -10.08
Current: -196.76
-185.54
-10.08
ROE (%) -43.37
NEPT's ROE (%) is ranked lower than
60% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. NEPT: -43.37 )
Ranked among companies with meaningful ROE (%) only.
NEPT' s 10-Year ROE (%) Range
Min: -596.63  Med: -51.58 Max: -9.66
Current: -43.37
-596.63
-9.66
ROA (%) -25.28
NEPT's ROA (%) is ranked higher than
50% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. NEPT: -25.28 )
Ranked among companies with meaningful ROA (%) only.
NEPT' s 10-Year ROA (%) Range
Min: -82.24  Med: -26.21 Max: -5.71
Current: -25.28
-82.24
-5.71
ROC (Joel Greenblatt) (%) -48.73
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. NEPT: -48.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NEPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1925.98  Med: -50.51 Max: -10.19
Current: -48.73
-1925.98
-10.19
Revenue Growth (3Y)(%) -20.60
NEPT's Revenue Growth (3Y)(%) is ranked lower than
68% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. NEPT: -20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NEPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 2.35 Max: 32
Current: -20.6
0
32
EBITDA Growth (3Y)(%) 58.70
NEPT's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. NEPT: 58.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NEPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -9.95 Max: 230.2
Current: 58.7
0
230.2
EPS Growth (3Y)(%) 111.80
NEPT's EPS Growth (3Y)(%) is ranked higher than
98% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. NEPT: 111.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NEPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.7  Med: 10.10 Max: 111.8
Current: 111.8
-47.7
111.8
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NEPT Guru Trades in Q2 2014

Jim Simons 40,900 sh (+102.48%)
» More
Q3 2014

NEPT Guru Trades in Q3 2014

Jim Simons 42,300 sh (+3.42%)
» More
Q4 2014

NEPT Guru Trades in Q4 2014

Jim Simons 53,800 sh (+27.19%)
» More
Q1 2015

NEPT Guru Trades in Q1 2015

Jim Simons 27,713 sh (-48.49%)
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 64.10
NEPT's Forward P/E is ranked lower than
83% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. NEPT: 64.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.63
NEPT's P/B is ranked higher than
71% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. NEPT: 2.63 )
Ranked among companies with meaningful P/B only.
NEPT' s 10-Year P/B Range
Min: 1.94  Med: 7.34 Max: 40.88
Current: 2.63
1.94
40.88
P/S 9.52
NEPT's P/S is ranked higher than
55% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. NEPT: 9.52 )
Ranked among companies with meaningful P/S only.
NEPT' s 10-Year P/S Range
Min: 0.91  Med: 8.40 Max: 33.87
Current: 9.52
0.91
33.87
Current Ratio 4.31
NEPT's Current Ratio is ranked lower than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. NEPT: 4.31 )
Ranked among companies with meaningful Current Ratio only.
NEPT' s 10-Year Current Ratio Range
Min: 0.4  Med: 2.67 Max: 5.93
Current: 4.31
0.4
5.93
Quick Ratio 2.93
NEPT's Quick Ratio is ranked lower than
60% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. NEPT: 2.93 )
Ranked among companies with meaningful Quick Ratio only.
NEPT' s 10-Year Quick Ratio Range
Min: 0.2  Med: 2.03 Max: 4.87
Current: 2.93
0.2
4.87
Days Inventory 250.82
NEPT's Days Inventory is ranked lower than
82% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. NEPT: 250.82 )
Ranked among companies with meaningful Days Inventory only.
NEPT' s 10-Year Days Inventory Range
Min: 58.23  Med: 107.59 Max: 272.09
Current: 250.82
58.23
272.09
Days Sales Outstanding 152.62
NEPT's Days Sales Outstanding is ranked lower than
85% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. NEPT: 152.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEPT' s 10-Year Days Sales Outstanding Range
Min: 77.93  Med: 94.85 Max: 159.39
Current: 152.62
77.93
159.39

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 19.86
NEPT's Price/Net Current Asset Value is ranked lower than
94% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. NEPT: 19.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NEPT' s 10-Year Price/Net Current Asset Value Range
Min: 4.17  Med: 13.82 Max: 84.63
Current: 19.86
4.17
84.63
Price/Tangible Book 2.44
NEPT's Price/Tangible Book is ranked higher than
76% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. NEPT: 2.44 )
Ranked among companies with meaningful Price/Tangible Book only.
NEPT' s 10-Year Price/Tangible Book Range
Min: 2.38  Med: 8.06 Max: 40.71
Current: 2.44
2.38
40.71
Price/Median PS Value 0.93
NEPT's Price/Median PS Value is ranked higher than
51% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. NEPT: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
NEPT' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 1.00 Max: 9
Current: 0.93
0.11
9
Earnings Yield (Greenblatt) (%) -21.57
NEPT's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NEPT: -21.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NEPT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -21.87  Med: 0.35 Max: 1.1
Current: -21.57
-21.87
1.1

Analyst Estimate

Feb16 Feb17 Feb18
EPS($) -0.13 0.03 0.14
EPS without NRI($) -0.13 0.03 0.14

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTB.Canada, NTU.Germany,
Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.
» More Articles for NEPT

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Neptune Announces First Quarter Results Jul 23 2015
Neptune Announces First Quarter Results Jul 13 2015
Acasti Announces First Quarter Results Jul 13 2015
US Patent Trial and Appeal Board Upholds Original Decision in Neptune's Favour Jul 09 2015
Neptune to Hold Conference Call to Discuss First Quarter Results Jul 03 2015
Neptune to Hold Conference Call to Discuss First Quarter Results Jun 29 2015
NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Financials Jun 03 2015
Acasti Announces Grant of Stock Options Jun 01 2015
Neptune Announces New Board of Director Nominees for Election at Annual and Special Meeting of... May 28 2015
Acasti Announces Fourth Quarter and Fiscal Year Results May 27 2015
Acasti Announces New Board of Director Nominees for Election at Annual and Special Meeting of... May 27 2015
Neptune Announces Fourth Quarter and Fiscal Year Results May 27 2015
Neptune Announces New Board of Director Nominees for Election at Annual and Special Meeting of... May 27 2015
Acasti Receives Extension to Regain Compliance With NASDAQ Minimum Bid Price Rule May 11 2015
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year Results May 07 2015
Acasti Announces Departure of Chief Financial Officer Apr 29 2015
Neptune Provides Business Update Apr 29 2015
Gian Franco Guerrieri Directs Neptune’s South American Business Development Apr 02 2015
Neptune to Present at 27th Annual Roth Conference Mar 29 2015
USPTO Issues Positive Decision that Triggers Royalty Payments to Neptune Mar 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK